Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. (DXCM) is widely described in its own communications as a global leader in glucose biosensing and real-time continuous glucose monitoring (CGM) for people with diabetes. The Dexcom news stream features regular updates on product launches, clinical evidence, coverage decisions, financial performance, and leadership developments, all centered on its CGM and biosensing technology.
Investors and healthcare observers following DXCM news will find detailed announcements on new products such as the Dexcom G7 15 Day CGM System, which is designed to provide real-time glucose readings over extended wear, and Dexcom Smart Basal, a CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes using long-acting insulin. News items also cover enhancements to the Stelo app for metabolic health, AI-enabled features like meal logging, and integrations with connected devices and insulin delivery systems.
Dexcom’s news releases highlight clinical and real-world data presented at major conferences, including the European Association for the Study of Diabetes (EASD), where the company shares findings on outcomes such as pregnancy complications, diabetic ketoacidosis management, and cost-effectiveness of CGM compared to fingersticks. Coverage and reimbursement milestones, such as expanded access under the Régie de l’assurance maladie du Québec (RAMQ) and other public programs, are also frequent topics.
Financial results and guidance updates, leadership transitions, and board appointments are reported through earnings releases and Form 8-K related press announcements. For anyone tracking how CGM technology, biosensing, and digital health tools are evolving in diabetes and metabolic health, the Dexcom news page offers an ongoing record of the company’s product, clinical, and corporate developments. Bookmark this page to follow the latest DXCM press releases and regulatory disclosures as they are issued.
DexCom, Inc. (Nasdaq: DXCM) anticipates fourth quarter 2021 preliminary revenue of approximately
DexCom, Inc. (NASDAQ:DXCM) announced that CEO Kevin Sayer will present at the 40th annual J.P. Morgan Healthcare Conference on January 10, 2022, starting at approximately 10:30 AM EST. The virtual presentation will be webcasted, and interested parties can access it through the DexCom Investor Relations website. DexCom is a leader in diabetes care technology, focusing on innovative continuous glucose monitoring (CGM) systems to improve diabetes management worldwide.
DexCom, Inc. (NASDAQ:DXCM) announced that Jereme Sylvain, CFO, will present an update at the 33rd Annual Piper Sandler Virtual Healthcare Conference on December 1, 2021, at 2:30 PM (ET). The presentation will be webcasted, and details can be found on the company's investor relations website.
Headquartered in San Diego, California, DexCom specializes in innovative continuous glucose monitoring (CGM) technologies, aiding diabetes management.
Dexcom (NASDAQ:DXCM) is promoting awareness during National Diabetes Awareness Month and World Diabetes Day by encouraging the diabetes community to engage in discussions about healthcare disparities.
Activities include a virtual Congressional testimony featuring Patti LaBelle advocating for better access to diabetes care, along with a campaign led by Nick Jonas on social media to highlight the experiences of people living with diabetes.
The focus is on improving global access to diabetes technology and emphasizing time in range as a key metric for diabetes management.
DexCom reported strong financial results for Q3 2021, with revenue of $650.2 million, a 30% increase from the prior year. U.S. revenue grew by 23%, while international revenues surged 57%. Operating income was $118.3 million, maintaining a healthy margin of 18.2%. DexCom received FDA clearance for two software solutions, enhancing its CGM ecosystem. The company also raised its full-year revenue guidance to approximately $2.425 - 2.450 billion with a projected growth rate of 26-27%.
DexCom (NASDAQ:DXCM) has launched its Time in Range Campaign in the UK, aimed at promoting awareness and adoption of the time-in-range metric in diabetes management. Despite the clinical benefits, a recent UK survey shows fewer than 50% of people with insulin-treated diabetes utilize this metric. Key findings reveal that 83% feel better when spending more time in range, yet 59% do not track it. Additionally, access to continuous glucose monitoring (CGM) technology varies significantly due to the UK's postcode lottery, affecting availability for many.
DexCom (NASDAQ:DXCM) will release its third quarter 2021 financial results after market close on October 28, 2021. A conference call to discuss the results will take place at 4:30 p.m. ET on the same day, with a webcast available on the DexCom investor relations website. Investors can join the call by dialing (800) 446-1671 or (847) 413-3362 for international calls, using confirmation number '49591484'. DexCom is a leader in diabetes management, providing innovative continuous glucose monitoring systems.
Dexcom (NASDAQ: DXCM) announces that the Dexcom G6 Continuous Glucose Monitoring (CGM) System is now eligible for provincial coverage in Manitoba for individuals with type 1 diabetes aged 25 and under. This move expands access to CGM technology, joining other provinces like British Columbia and Quebec that already provide coverage. The Dexcom G6 system allows users to monitor glucose levels continuously, reducing reliance on fingerstick tests. The initiative aims to improve diabetes management and health outcomes for young individuals with diabetes in Manitoba.
Dexcom (NASDAQ: DXCM) announces its G6 Continuous Glucose Monitoring (CGM) System is now covered by the Non-Insured Health Benefits (NIHB) Program for children and adolescents aged 2-19 requiring intensive insulin therapy. This coverage aims to improve access for First Nations and Inuit communities, potentially enhancing health outcomes for those living with diabetes. With proven benefits in glycemic control, the Dexcom G6 System provides real-time data and alerts, facilitating better diabetes management and support for families.
DexCom, Inc. (NASDAQ:DXCM) announced upcoming presentations at virtual investor conferences. Jereme Sylvain, CFO, will present at the Wells Fargo 2021 Virtual Healthcare Conference on September 10, 2021, at 2:00 PM EST. Quentin Blackford, COO, will present at the Morgan Stanley 19th Annual Healthcare Conference on September 13, 2021, at 2:00 PM EST. Webcasts will be available on the DexCom Investor Relations site for live viewing and future reference.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
